Skip to main content

Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal

Written by Customer Service on . Posted in Public Companies.

YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2020 in the medium-sized company category for the third year in a row.“We are extremely proud of the culture we have built at Optinose over the last ten years. Even during these extraordinary times, maintaining a fun and productive work environment in which people can come together and accomplish great things continues to be our highest priority,” said Peter Miller, CEO of Optinose. “We are excited to be recognized once again as a ‘Best Place to Work’ by the Philadelphia Business Journal. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives.”“Public recognition of Optinose as a ‘Best Place to Work’ is an honor for all of us, and is only possible because of the collective commitment and contributions of our team,” added Ramy Mahmoud, MD, President and Chief Operating Officer of Optinose. “It is especially heartening that even during this uniquely fraught time in history, nearly 84% of our colleagues chose to participate in this year’s survey. We truly value colleague feedback and make concrete action plans based on the feedback from this survey. Employee engagement is a top priority: it starts with our hiring process and permeates everything we do thereafter. Nurturing a team of high-achieving professionals who are passionately motivated to improve human health, and who share clearly articulated core values, is essential to our success in developing and commercializing innovative new products.”Optinose has grown tremendously over the past several years, and currently has more than 200 colleagues, with nearly 80 based in the headquarters in Yardley. The Company has achieved key objectives in support of the launch of its lead product XHANCE® and the conduct of multiple clinical trials. More information about the shared purpose that unites the people of Optinose is here, and more information about career opportunities is here.The Philadelphia Business Journal names companies to its “Best Places to Work” list using a rigorous scientific process based on responses to an independent employee engagement survey conducted by Quantum Workplace. As part of the survey, employees rate the company in areas including communication and resources, individual needs, manager effectiveness, personal engagement, team dynamics, and trust in leadership.About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.